BIOMAT Database Logo BIOMAT Database Logo

The effect of pyrazinamide, rifampicin and cycloserine on the blood levels and urinary excretion of isoniazid. 1971

V M Venho, and R Koskinen

UI MeSH Term Description Entries
D007538 Isoniazid Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. Isonicotinic Acid Hydrazide,Ftivazide,Isonex,Isonicotinic Acid Vanillylidenehydrazide,Phthivazid,Phthivazide,Tubazide,Acid Vanillylidenehydrazide, Isonicotinic,Hydrazide, Isonicotinic Acid,Vanillylidenehydrazide, Isonicotinic Acid
D011718 Pyrazinamide A pyrazine that is used therapeutically as an antitubercular agent. Tisamid
D003523 Cycloserine Antibiotic substance produced by Streptomyces garyphalus. R-4-Amino-3-isoxazolidinone,Seromycin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012293 Rifampin A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) Rifampicin,Benemycin,Rifadin,Rimactan,Rimactane,Tubocin
D014376 Tuberculosis Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS. Koch's Disease,Kochs Disease,Mycobacterium tuberculosis Infection,Infection, Mycobacterium tuberculosis,Infections, Mycobacterium tuberculosis,Koch Disease,Mycobacterium tuberculosis Infections,Tuberculoses

Related Publications

V M Venho, and R Koskinen
The effect of pyrazinamide and rifampicin on isoniazid metabolism in rats.
September 2007, Biopharmaceutics & drug disposition,
V M Venho, and R Koskinen
The effect of rifampicin and pyrazinamide on isoniazid pharmacokinetics in rats.
November 2007, Biopharmaceutics & drug disposition,
V M Venho, and R Koskinen
Triple therapy with isoniazid, rifampicin and pyrazinamide.
December 1988, Bulletin of the International Union against Tuberculosis and Lung Disease,
V M Venho, and R Koskinen
[Hepatotoxic effect of a combination of pyrazinamide with isoniazid and rifampicin].
January 1989, Problemy tuberkuleza,
V M Venho, and R Koskinen
Urinary excretion of rifampicin and its metabolites as an index of rifampicin blood levels.
December 1970, The New Zealand medical journal,
V M Venho, and R Koskinen
Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide.
April 1995, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,
V M Venho, and R Koskinen
Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.
October 2002, International journal of clinical pharmacology and therapeutics,
V M Venho, and R Koskinen
Serum levels, urinary excretion, and side-effects of cycloserine in the presence of isoniazid and p-aminosalicylic acid.
January 1969, Scandinavian journal of respiratory diseases,
V M Venho, and R Koskinen
Effect of antituberculous drugs, isoniazid, pyrazinamide and rifampicin, on chemiluminescence of the human polymorphonuclear leukocytes.
January 1995, Folia biologica,
V M Venho, and R Koskinen
Liquid chromatographic determination of isoniazid, pyrazinamide and rifampicin from pharmaceutical preparations and blood.
January 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences,
Copied contents to your clipboard!